A new study published in the November 29, 2013 edition of the journal Science, sheds new light on a woman's risk of developing breast cancer. The study, for the first time, explains the reason behind the established relationship between high cholesterol and breast cancer -- especially in obese women who have reached menopause.
Researchers from Duke Cancer Institute in North Carolina found that a primary…Continue
Added by Editorial Team on November 28, 2013 at 4:00pm — No Comments
Researchers involved in epidemiological studies looking at the potential contributions to breast cancer risk have not been able to provided conclusive evidence linking dietary fat intake and obesity to breast cancer risk. In the pooled analysis of data from large, prospective cohort studies, high BMI (≥25 kg/m2) was a recognized risk factor for postmenopausal breast cancer . Conversely, in the same analysis, high BMI (>31) is associated with reduced risk for premenopausal breast…Continue
Added by Editorial Team on November 26, 2013 at 9:00pm — No Comments
For many years, scientists have observed that breast tumor from certain breast cancer patients with aggressive - metastatic - undergo epithelial-to-mesenchymal transition or EMT which makes them resistant to therapies targeted to the primary cancer. They also observed that breast cancer contained low levels of mitochondrial DNA or mtDNA. However, until recently, the mechanistic link between mtDNA reduction, often seen in breast cancer patients, and EMT was unknown. No one was able to…Continue
Added by Editorial Team on November 8, 2013 at 12:00pm — No Comments
Genomic testing,a type of medical test that identifies changes in chromosomes, genes, or proteins, could allow many patients with early breast cancer to safely avoid chemotherapy. This is the preliminary conclusion from a new trial, reported in Amsterdam, The Netherlands, at the European Cancer Congress 2013 this week.  The results illustrate that more research is urgently needed to compare and validate the growing number of genomic tests becoming available in oncology.…Continue
Added by Editorial Team on October 1, 2013 at 8:00pm — No Comments
A multitude of medical studies have shown that a woman’s risk of developing breast cancer is directly related to her exposure to endogenous estrogen and progesterone, hormones that are produced by her ovaries. These ovarian hormones stimulate cell growth. Reproductive factors that increase the duration and/or levels of exposure to these hormones, include early onset of menstruation, late onset of menopause, later age at first pregnancy, and never having given birth have been associated…Continue
Added by Editorial Team on October 1, 2013 at 12:00pm — No Comments
Earlier today, the U.S. Food and Drug Administration (FDA) granted accelerated approval of a pertuzumab (Perjeta®, Genentech/Roche) regimen for neoadjuvant treatment in patients with high-risk, HER2-positive early stage breast cancer.
Breast cancer is the most common cancer among women worldwide. According to the American Cancer Society, approximately 235,000 people in the United States will be diagnosed with breast cancer, and 40,000 will die from the disease in 2013. In…Continue
Added by Editorial Team on September 30, 2013 at 9:30pm — No Comments
Diabetes and cancer are common diseases with tremendous impact on health and healthcare worldwide expenditure. A growing number of epidemiological and clinical studies find evidence suggesting that diabetes is directly linked to an increased risk of developing certain types of cancer. Now, researchers in The Netherlands have performed a unique meta-analysis that excludes all other causes of death and found that diabetic patients not only have an increased risk of developing breast and…Continue
Added by Editorial Team on September 28, 2013 at 10:30am — No Comments
According to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting, being held in Atlanta,September 22-25, 2013, early-stage breast cancer patients who receive external beam therapy or XRT are not at higher risk for serious long-term side effects in the chest area, including increase in deaths from cardiac disease and secondary malignancies.
Various studies have shown that…Continue
Added by Peter Hofland, PhD on September 24, 2013 at 8:30am — No Comments
Breast cancer is the most common cancer among women worldwide. According to the American Cancer Society (ACS), approximately 235,000 women in the United States will be diagnosed with breast cancer. Based on long-term data, it is expected that in 2013 40,000 will die from the disease in the U.S. alone. 
Once breast cancer becomes metastatic, it is…Continue
Added by Peter Hofland, PhD on September 19, 2013 at 6:00pm — No Comments
The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 13 to 0, with one abstention, in favor of recommending accelerated approval of a regimen of pertuzumab (Perjeta®, Genentech/Roche) for neoadjuvant treatment in women with high-risk, HER2-positive early stage breast cancer.
Breast cancer is the most common cancer among women worldwide.…Continue
Added by Peter Hofland, PhD on September 12, 2013 at 8:00pm — No Comments
A new injectable (subcutaneous) formulation of trastuzumab (Herceptin; Roche/Genentech) has been approved by the European Commission for the treatment of HER2-positive breast cancer, an aggressive sub-type of the disease. The approval is for both early and later stages of treatment.
“More than 90,000 women in Europe are diagnosed with HER2 positive breast cancer every year,” said Hal Barron, MD, Chief Medical Officer and Head of Global Product Development at Roche. “This new,…Continue
Added by Peter Hofland, PhD on September 2, 2013 at 10:00pm — No Comments
It's a real sobering fact for millions of young women heading back to school or college. Researcher have found a link confirming that alcohol consumption before motherhood increases their risk of future breast cancer.
The conclusions stem from new research conducted by researchers at the Washington University School of Medicine in St. Louis that, for the first time, links increased breast cancer risk to alcohol consumption between early adolescence and first…Continue
Added by Editorial Team on August 28, 2013 at 2:30pm — No Comments
In an unexpected finding, scientists have linked the activation of a stress gene in immune system cells to the spread of breast cancer to other parts of the body. Researchers say the study suggests this gene, called ATF3, may be the crucial link between stress and cancer, including the major cause of cancer death – its spread, or metastasis. Previous public health studies have shown that stress is a risk factor for cancer. The findings were published in the July 1, 2013 edition of the…Continue
It's an intriguing question that needs to be asked: If two women have the same genetic mutation that puts them at higher-than-average risk for a disease such as breast cancer, why does only one develop the disease?Continue
Added by Editorial Team on August 1, 2013 at 11:30am — No Comments
A study published in the July 17, 2013 issue of Journal of the National Cancer Institute (JNCI)  shows that the addition of the erythropoiesis-stimulating agent (ESA) epoetin alfa (Epogen®, Amgen; Eprex®, Janssen-Cilag; Procrit®, Janssen Products) to the chemotherapy regimen in…Continue
Added by Editorial Team on July 17, 2013 at 5:30pm — No Comments
ASCO President Sandra M. Swain, MD, FACP, introduces various study related to breast cancer research presented during the 49th Annual Meeting of the American Society of Clinical Oncology, being held in Chicago, May 31 - June 4, 2013.
Added by Editorial Team on June 3, 2013 at 5:30pm — No Comments
An European phase III clinical trial called AMAROS, which was, in part supported by the European Organization for Research and Treatment of Cancer (EORTC) Charitable Trust, found that axillary radiotherapy (ART) and lymph node surgery or axillary lymph node dissection (ALND) result in equivalent overall and disease-free survival at five years after treatment for women with sentinel lymph node positive…Continue
Added by Editorial Team on June 3, 2013 at 2:00pm — No Comments
A genomic profiling study of African American women with breast cancer who were referred for genetic counseling at The University of Chicago, supported, in part, by the National Institutes of Health, the Breast Cancer Research Foundation, and Komen for the Cure, finds that about one in five carries an inherited abnormality in at least one of 18 genes associated with breast cancer susceptibility. The study results were presented at the 49th Annual Meeting of the…Continue
Added by Editorial Team on June 3, 2013 at 1:30pm — No Comments
Results from a recent, phase III, randomized clinical trial, supported, in part, the National Cancer Institute and Amgen, shows that low-dose weekly administration of adjuvant paclitaxel (Taxol®, Bristol-Myers Squibb Company) vs. standard, every two weeks administration in women with higher-risk…Continue
Added by Editorial Team on June 3, 2013 at 12:30pm — No Comments
Results from the British aTTom trial, presented during the 49th Annual Meeting of the American Society of Clinical Oncology, shows that 10 years of adjuvant treatment with tamoxifen (Nolvadex®, Istubal®, Valodex®; AstraZeneca) provides women with estrogen-receptor-positive (ER+) breast cancer greater protection against late recurrence and death from breast cancer than does the current standard of only five years of tamoxifen. The study…Continue
Added by Editorial Team on June 2, 2013 at 9:30am — No Comments